TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Components: The biocomponent is probiotic. Preferred Method: In the process (P1), bacteria used for the incubation step have been pre-treated for increasing the sugar-rich structures in their cell envelope by fermentation under a C/N ratio of at least 10:1, in the presence of a fermentable sugar at a concentration of at least 20 (preferably more than 50) g/liter, until their dry weight is increased by at least 200%, for at least 10 hours, at 4-40 degrees C; or by acidic hydrolysis of glycocalyx, cell envelope and/or S-layer, at above 35 degrees C.    TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Components: The silver nanoparticles having an isoelectric point of 3-7, average particle size of 1-8 nm, and BET of 30-90 m2/g. The silver nanoparticles are distributed on or inside the cell envelope or S-layer or glycocalyx of the biocomponent. The concentrated alkali metal hydroxide is 0.01-2 (preferably 0.5-2) N sodium hydroxide. The concentrated inorganic strong acid is 1-10N sulfuric acid. The weight ratio of the first fraction (i) to the second fraction (ii) is higher than 1:1. Preferred Method: The process (P1) further involves extracting the Ag(0) silver nanoparticles from the biomass by means of concentrated alkali metal hydroxide or concentrated inorganic acid or enzymes; centrifugation or filtration of a slurry of the extracted Ag(0) silver nanoparticles, where the extraction step produces (i) a first fraction of silver nanoparticles with an average particle size of 1-8 nm and is associated with the cell envelope or glycocalyx and/or S-layer of the bacteria and (ii) a second fraction of silver nanoparticles with an average particle size of 20-200 nm and is associated with the cytoplasm of the bacteria; and separating the first fraction (i) from the second fraction (ii). The second fraction (ii) is introduced as a component of a conductive ink or a catalyst. The first fraction (i) and/or second fraction (ii) are introduced as a component of an anti-microbial composition. In the process (P1), the extraction step is performed by using concentrated alkali metal hydroxide for at least 5 minutes at temperature of at least 70 degrees C; or by using concentrated inorganic strong acid at 0-100 degrees C. In the process (P1), the incubation step is performed for at least one hour at 10-40 degrees C, in the absence of an externally added reducing agent or a capping agent (such as surfactant).    TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition (C1) further comprises at least one other anti-microbial agent; and where the silver nanoparticles are combined with a zeolite or celite. ACTIVITY - Antibacterial; Fungicide; Antialgal. The efficacy of extracted silver nanoparticles against Pseudomonas aeruginosa by using standard assay and minimum inhibitory concentration (MIC) was measured. The extracted silver nanoparticles showed MIC of 4.3 (unit not defined).    MECHANISM OF ACTION - None given.    EXAMPLE - No suitable example given.